title: Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature.
abstract: OBJECTIVE
  We systematically reviewed the evidence for the efficacy and safety of botulinum toxin in the management of overactive bladder.
  
  
  METHODS
  We performed a systematic review of the literature to identify articles published between 1985 and March 2009 on intravesical botulinum toxin-A injections for the treatment of refractory idiopathic overactive bladder in men and women. Databases searched included MEDLINE, CENTRAL and Embase. Data were tabulated from case series and from randomized controlled trials, and data were pooled where appropriate.
  
  
  RESULTS
  Our literature search identified 432 titles and 23 full articles were included in the final review. Three randomized placebo controlled trials addressing the use of botulinum toxin-A were identified (99 patients total). The pooled random effects estimate of effect across all 3 studies was 3.88 (95% CI -6.15, -1.62), meaning that patients treated with botulinum toxin-A had 3.88 fewer incontinence episodes per day. Urogenital Distress Inventory data revealed significant improvements in quality of life compared with placebo with a standardized mean difference of -0.62 (CI -1.04, -0.21). Data from case series demonstrated significant improvements in overactive bladder symptoms and quality of life, despite heterogeneity in methodology and case mix. However, based on the randomized controlled trials there was a 9-fold increased odds of increased post-void residual after botulinum toxin-A compared with placebo (8.55; 95% CI 3.22, 22.71).
  
  
  CONCLUSIONS
  Intravesical injection of botulinum toxin resulted in improvement in medication refractory overactive bladder symptoms. However, the risk of increased post-void residual and symptomatic urinary retention was significant. Several questions remain concerning the optimal administration of botulinum toxin-A for the patient with overactive bladder.
authors.affiliation: Department of Urology, University of California Los Angeles, Los Angeles, California, USA. janger@mednet.ucla.edu
authors.forename: Jennifer T
authors.initials: JT
authors.lastname: Anger
authors.forename: Aviva
authors.initials: A
authors.lastname: Weinberg
authors.forename: Marika J
authors.initials: MJ
authors.lastname: Suttorp
authors.forename: Mark S
authors.initials: MS
authors.lastname: Litwin
authors.forename: Paul G
authors.initials: PG
authors.lastname: Shekelle
mesh_terms: D000283:Administration, Intravesical; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D006801:Humans; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005493
references.pmid: 17636801
references.citation: Eur Urol. 2009 Jan;55(1):100-19
references.pmid: 18823697
references.citation: J Urol. 2007 Jun;177(6):2231-6
references.pmid: 17509328
references.citation: J Clin Epidemiol. 2006 Jan;59(1):7-10
references.pmid: 16360555
references.citation: J Urol. 2009 Jun;181(6):2608-15
references.pmid: 19375091
references.citation: J Urol. 2008 Jul;180(1):217-22
references.pmid: 18499184
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: BMC Med Res Methodol. 2007 Feb 15;7:10
references.pmid: 17302989
references.citation: Mayo Clin Proc. 2002 Apr;77(4):371-83
references.pmid: 11936935
references.citation: J Urol. 2004 Jul;172(1):240-3
references.pmid: 15201783
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Biometrics. 1994 Dec;50(4):1088-101
references.pmid: 7786990
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71
references.pmid: 2858114
references.citation: J Urol. 2000 Sep;164(3 Pt 1):692-7
references.pmid: 10953127